vs
Side-by-side financial comparison of Energy Services of America CORP (ESOA) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Energy Services of America CORP is the larger business by last-quarter revenue ($114.1M vs $86.8M, roughly 1.3× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 13.4%). Energy Services of America CORP produced more free cash flow last quarter ($16.8M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 26.7%).
Superior Energy Services is an American oil services company that operates as a holding company for a portfolio of oilfield equipment rentals and well oil and gas services brands.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
ESOA vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $114.1M | $86.8M |
| Net Profit | — | — |
| Gross Margin | 12.3% | 67.4% |
| Operating Margin | 4.3% | -84.7% |
| Net Margin | — | — |
| Revenue YoY | 13.4% | 17.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.16 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $114.1M | $86.8M | ||
| Q3 25 | $130.1M | $67.5M | ||
| Q2 25 | $103.6M | $60.0M | ||
| Q1 25 | $76.7M | $49.3M | ||
| Q4 24 | $100.6M | $73.7M | ||
| Q3 24 | $104.7M | $58.6M | ||
| Q2 24 | $85.9M | $31.1M | ||
| Q1 24 | $71.1M | $715.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-91.3M | ||
| Q2 25 | — | $-111.7M | ||
| Q1 25 | — | $-116.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-83.5M | ||
| Q2 24 | — | $-97.1M | ||
| Q1 24 | — | $-113.0M |
| Q4 25 | 12.3% | 67.4% | ||
| Q3 25 | 12.6% | 43.0% | ||
| Q2 25 | 11.6% | 5.5% | ||
| Q1 25 | 0.1% | -0.8% | ||
| Q4 24 | 10.2% | 68.7% | ||
| Q3 24 | 16.8% | 46.2% | ||
| Q2 24 | 17.8% | -0.8% | ||
| Q1 24 | 8.8% | — |
| Q4 25 | 4.3% | -84.7% | ||
| Q3 25 | 5.8% | -140.7% | ||
| Q2 25 | 3.1% | -189.8% | ||
| Q1 25 | -10.6% | -245.8% | ||
| Q4 24 | 1.6% | -117.5% | ||
| Q3 24 | 8.4% | -152.1% | ||
| Q2 24 | 9.9% | -327.6% | ||
| Q1 24 | -1.5% | -16464.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | -135.3% | ||
| Q2 25 | — | -186.2% | ||
| Q1 25 | — | -235.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -142.7% | ||
| Q2 24 | — | -312.2% | ||
| Q1 24 | — | -15800.8% |
| Q4 25 | $0.16 | — | ||
| Q3 25 | $0.26 | — | ||
| Q2 25 | $0.12 | $-0.33 | ||
| Q1 25 | $-0.41 | $-0.36 | ||
| Q4 24 | $0.05 | $-0.24 | ||
| Q3 24 | $0.40 | $-0.28 | ||
| Q2 24 | $1.06 | $-0.34 | ||
| Q1 24 | $-0.07 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.7M | $297.0M |
| Total DebtLower is stronger | $62.0M | — |
| Stockholders' EquityBook value | $60.6M | $698.6M |
| Total Assets | $201.0M | $913.2M |
| Debt / EquityLower = less leverage | 1.02× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.7M | $297.0M | ||
| Q3 25 | $12.2M | $300.8M | ||
| Q2 25 | $15.3M | $301.2M | ||
| Q1 25 | $9.9M | $359.7M | ||
| Q4 24 | $20.3M | $323.8M | ||
| Q3 24 | $12.9M | $397.5M | ||
| Q2 24 | $14.5M | $412.5M | ||
| Q1 24 | $12.1M | $356.2M |
| Q4 25 | $62.0M | — | ||
| Q3 25 | $72.2M | — | ||
| Q2 25 | $59.1M | — | ||
| Q1 25 | $50.7M | — | ||
| Q4 24 | $59.6M | — | ||
| Q3 24 | $33.9M | — | ||
| Q2 24 | $31.9M | — | ||
| Q1 24 | $45.7M | — |
| Q4 25 | $60.6M | $698.6M | ||
| Q3 25 | $59.2M | $702.3M | ||
| Q2 25 | $54.4M | $698.5M | ||
| Q1 25 | $53.7M | $767.9M | ||
| Q4 24 | $61.0M | $710.4M | ||
| Q3 24 | $58.7M | $773.5M | ||
| Q2 24 | $52.0M | $768.5M | ||
| Q1 24 | $34.6M | $680.0M |
| Q4 25 | $201.0M | $913.2M | ||
| Q3 25 | $215.2M | $904.9M | ||
| Q2 25 | $189.1M | $907.4M | ||
| Q1 25 | $170.2M | $966.7M | ||
| Q4 24 | $192.1M | $910.4M | ||
| Q3 24 | $158.2M | $991.1M | ||
| Q2 24 | $148.8M | $964.3M | ||
| Q1 24 | $136.1M | $869.8M |
| Q4 25 | 1.02× | — | ||
| Q3 25 | 1.22× | — | ||
| Q2 25 | 1.09× | — | ||
| Q1 25 | 0.94× | — | ||
| Q4 24 | 0.98× | — | ||
| Q3 24 | 0.58× | — | ||
| Q2 24 | 0.61× | — | ||
| Q1 24 | 1.32× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.8M | $-52.6M |
| Free Cash FlowOCF − Capex | $16.8M | $-61.9M |
| FCF MarginFCF / Revenue | 14.7% | -71.3% |
| Capex IntensityCapex / Revenue | 1.8% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $3.1M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.8M | $-52.6M | ||
| Q3 25 | $-9.3M | $-78.7M | ||
| Q2 25 | $3.4M | $-67.4M | ||
| Q1 25 | $1.1M | $-103.7M | ||
| Q4 24 | $8.9M | $-73.3M | ||
| Q3 24 | $-847.5K | $-59.0M | ||
| Q2 24 | $19.3M | $-98.4M | ||
| Q1 24 | $-2.7M | $-122.3M |
| Q4 25 | $16.8M | $-61.9M | ||
| Q3 25 | $-12.0M | $-89.5M | ||
| Q2 25 | $-582.0K | $-74.9M | ||
| Q1 25 | $-1.1M | $-109.9M | ||
| Q4 24 | $6.0M | $-77.5M | ||
| Q3 24 | $-2.9M | $-61.3M | ||
| Q2 24 | $16.3M | $-98.9M | ||
| Q1 24 | $-4.9M | $-126.5M |
| Q4 25 | 14.7% | -71.3% | ||
| Q3 25 | -9.3% | -132.7% | ||
| Q2 25 | -0.6% | -124.9% | ||
| Q1 25 | -1.4% | -222.8% | ||
| Q4 24 | 5.9% | -105.1% | ||
| Q3 24 | -2.8% | -104.6% | ||
| Q2 24 | 18.9% | -317.9% | ||
| Q1 24 | -6.9% | -17685.3% |
| Q4 25 | 1.8% | 10.7% | ||
| Q3 25 | 2.1% | 16.1% | ||
| Q2 25 | 3.9% | 12.4% | ||
| Q1 25 | 2.9% | 12.6% | ||
| Q4 24 | 2.9% | 5.7% | ||
| Q3 24 | 2.0% | 3.9% | ||
| Q2 24 | 3.6% | 1.4% | ||
| Q1 24 | 3.1% | 583.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESOA
| Electricals Mechanical And General | $49.4M | 43% |
| Gas And Petroleum Transmission | $24.1M | 21% |
| Cost Plus And TM Contracts | $23.3M | 20% |
| Transferred At Point In Time | $17.9M | 16% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
